DK3297651T3 - Synergistisk kombination af neuronale levedygtighedsfaktorer og anvendelser deraf - Google Patents
Synergistisk kombination af neuronale levedygtighedsfaktorer og anvendelser deraf Download PDFInfo
- Publication number
- DK3297651T3 DK3297651T3 DK16724409.4T DK16724409T DK3297651T3 DK 3297651 T3 DK3297651 T3 DK 3297651T3 DK 16724409 T DK16724409 T DK 16724409T DK 3297651 T3 DK3297651 T3 DK 3297651T3
- Authority
- DK
- Denmark
- Prior art keywords
- liveless
- neuronal
- factors
- applications
- synergistic combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2015/000967 WO2016185242A1 (en) | 2015-05-21 | 2015-05-21 | Synergistic combination of neuronal viability factors and uses thereof |
PCT/EP2016/061488 WO2016185037A1 (en) | 2015-05-21 | 2016-05-20 | Synergistic combination of neuronal viability factors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3297651T3 true DK3297651T3 (da) | 2020-05-25 |
Family
ID=54361112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16724409.4T DK3297651T3 (da) | 2015-05-21 | 2016-05-20 | Synergistisk kombination af neuronale levedygtighedsfaktorer og anvendelser deraf |
Country Status (8)
Country | Link |
---|---|
US (1) | US10668129B2 (da) |
EP (1) | EP3297651B1 (da) |
JP (1) | JP6684343B2 (da) |
CA (1) | CA2986630C (da) |
DK (1) | DK3297651T3 (da) |
ES (1) | ES2792905T3 (da) |
IL (1) | IL255816B (da) |
WO (2) | WO2016185242A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2027889A1 (en) * | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
WO2017120294A1 (en) | 2016-01-05 | 2017-07-13 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treatment of ocular disorders and blinding diseases |
DK3728610T5 (da) * | 2017-12-22 | 2024-08-26 | Sparingvision | Konstrukter omfattende neuronale viabilitetsfaktorer og anvendelser heraf |
WO2020079464A1 (en) | 2018-10-17 | 2020-04-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating retinal degeneration disease by administering nucleolin polynucleotide or polypeptide |
AU2020232692A1 (en) | 2019-03-04 | 2021-09-30 | The Trustees Of The University Of Pennsylvania | Neuroprotective gene therapy targeting the AKT pathway |
US20220226507A1 (en) * | 2019-05-17 | 2022-07-21 | Research Institute At Nationwide Children's Hospital | Optimized gene therapy targeting retinal cells |
EP4074828A4 (en) * | 2019-12-09 | 2023-12-27 | Chigenovo Co., Ltd. | USE OF CYP4V2 AND RDCVF FOR PRODUCING MEDICINAL PRODUCTS |
US20240197913A1 (en) | 2021-04-20 | 2024-06-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for treating retinal degenerative disorders |
WO2024084075A1 (en) | 2022-10-20 | 2024-04-25 | Sparingvision | Compositions and methods for treating retinal degenerative disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2823221B1 (fr) * | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
EP2027889A1 (en) | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
US9249425B2 (en) | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
KR102000141B1 (ko) * | 2011-10-27 | 2019-07-15 | 웰스테이트 옵탈믹스 코퍼레이션 | 간상세포 유래 원추세포 생존능 인자를 인코딩하는 벡터 |
DK2909232T3 (da) * | 2012-10-17 | 2020-06-08 | Inst Nat Sante Rech Med | Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af aldersrelateret makuladegeneration (amd) |
-
2015
- 2015-05-21 WO PCT/IB2015/000967 patent/WO2016185242A1/en active Application Filing
- 2015-05-21 JP JP2018512504A patent/JP6684343B2/ja active Active
-
2016
- 2016-05-20 DK DK16724409.4T patent/DK3297651T3/da active
- 2016-05-20 CA CA2986630A patent/CA2986630C/en active Active
- 2016-05-20 WO PCT/EP2016/061488 patent/WO2016185037A1/en active Application Filing
- 2016-05-20 US US15/576,027 patent/US10668129B2/en active Active
- 2016-05-20 EP EP16724409.4A patent/EP3297651B1/en active Active
- 2016-05-20 ES ES16724409T patent/ES2792905T3/es active Active
-
2017
- 2017-11-21 IL IL255816A patent/IL255816B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP2018515622A (ja) | 2018-06-14 |
WO2016185242A1 (en) | 2016-11-24 |
EP3297651A1 (en) | 2018-03-28 |
US20180153962A1 (en) | 2018-06-07 |
JP6684343B2 (ja) | 2020-04-22 |
ES2792905T3 (es) | 2020-11-12 |
CA2986630C (en) | 2021-03-23 |
WO2016185037A1 (en) | 2016-11-24 |
US10668129B2 (en) | 2020-06-02 |
EP3297651B1 (en) | 2020-02-26 |
IL255816B (en) | 2020-08-31 |
IL255816A (en) | 2018-01-31 |
CA2986630A1 (en) | 2016-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3283107T3 (da) | Sammensætninger omfattende en kombination af ipilimumab og nivolumab | |
IL293377A (en) | Hsd17b13 variants and uses thereof | |
DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
DK3872085T3 (da) | Stam-virussekvenser og anvendelser heraf | |
DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
RS62164B1 (sr) | Sulfoniluree i srodna jedinjenja i njihova upotreba | |
DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3227237T3 (da) | Indretning og anvendelse deraf til uv-bearbejdning af fluider | |
DK3288553T3 (da) | Kombinationer af cannabinoider og n-acylethanolaminer | |
DK3297651T3 (da) | Synergistisk kombination af neuronale levedygtighedsfaktorer og anvendelser deraf | |
DK3364958T3 (da) | Modulatorer af sestrin-gator2-interaktion og anvendelser deraf | |
DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
DK3558280T3 (da) | Forebyggelse og behandling af migræne | |
DK3269809T3 (da) | MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
EP3481952A4 (en) | METHYLATION MARKERS IN THE TREATMENT OF LEUKEMIA AND USES THEREOF | |
DK3384079T3 (da) | Fibrøs konstruktion og fremgangsmåder i forbindelse hermed | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
DK3265126T3 (da) | Kombinationsformulering af tesofensin og metoprolol | |
DK3316951T3 (da) | Eyewear and flexible elements |